ArticleIrish journal of medical science2025
miR-326 serves as a diagnostic biomarker in gestational diabetes mellitus and its regulatory effect on trophoblast cell viability.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating miR-326 and miR-532-3p: novel biomarkers for early gestational diabetes mellitus detection with high diagnostic accuracy.Journal of endocrinological investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the diagnostic value and mechanism of action of miR-326 in gestational diabetes mellitus (GDM).
methodsThe study population consisted of 98 GDM patients and 71 healthy pregnant women. Subjects' serum were collected early in pregnancy (10-12 weeks) for cryopreservation. Gene expression was analyzed by RT-qPCR. miR-326 was evaluated by ROC for its diagnostic value. Pearson correlation analysis was performed to calculate the relationship between miR-326 and glycemic index and TLR4. Logistic analysis resulted in risk factors for adverse pregnancy outcomes. CCK8, transwell, and flow cytometry were performed to observe changes in trophoblast function after different treatments. DLR verified the targeting relationship between genes.
resultsmiR-326 is upregulated in early pregnancy serum of GDM patients and has a predictive diagnostic value for GDM. There is a positive correlation between miR-326 and glycemic indices (HbA1c, FBG, HOMA-IR) in GDM patients, which is a risk factor for inducing adverse pregnancy outcomes. miR-326 inhibitor restored the proliferation, migration, and invasion ability of high glucose-treated (HG group) cells and reduced apoptosis. TLR4 is a target gene of miR-326, and the expression of the two is negatively correlated in GDM patients. Transfection of si-TLR4 resisted the changes in trophoblast cells induced by the use of miR-326 inhibitor.
conclusionHigh levels of miR-326 are upregulated in serum of GDM patients in early pregnancy. miR-326 targeted inhibition of TLR4 causes abnormal trophoblast cell function and induces adverse pregnancy outcomes in GDM patients.
Indexed as
Identifiers
40853417What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.